<SEC-DOCUMENT>0001193125-16-785649.txt : 20161206
<SEC-HEADER>0001193125-16-785649.hdr.sgml : 20161206
<ACCEPTANCE-DATETIME>20161206070138
ACCESSION NUMBER:		0001193125-16-785649
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20161206
FILED AS OF DATE:		20161206
DATE AS OF CHANGE:		20161206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		162035150

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 5
		STREET 2:		20 GEORGE STREET
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 5
		STREET 2:		20 GEORGE STREET
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d283688d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>FORM 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of December, 2016 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Novogen
Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 5, 20 George Street, Hornsby, NSW 2077, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Novogen Limited </B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Kate Hill </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kate Hill </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interim Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 6 December 2016 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g283688txpg3a.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ASX:NRT</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NASDAQ:NVGN</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Ltd</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Company)</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ABN 37 063 259 754</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital Structure</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary&nbsp;Shares&nbsp;on&nbsp;issue:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">483 M</P> <P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr John O&#146;Connor</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairman</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Bryce Carmine</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deputy Chairman</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr James Garner</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Managing Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Ian Phillips MNZM</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Iain Ross</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Steven Coffey</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MARKET RELEASE</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6&nbsp;December 2016</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOVOGEN ENROLS FIRST PATIENT INTO INTERNATIONAL PHASE I STUDY OF
CANTRIXIL<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> IN OVARIAN CANCER</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cantrixil (TRX-E-002-1) is one of Novogen&#146;s four oncology development
candidates, and is being developed as a therapy for patients with ovarian cancer</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Phase I study is designed primarily to understand the safety and tolerability of
Cantrixil in ovarian cancer patients, and will be run at hospitals in US and Australia</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is anticipated that up to 60 patients will be recruited and the study will run
for approximately 18 months</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sydney, 6 December 2016 &#150; Australian
oncology-focused biotechnology company Novogen Ltd (ASX: NRT; NASDAQ: NVGN) today announced that it had enrolled the first patient into its first-in-human, phase I clinical study for Cantrixil (TRX-E-002-1) in ovarian cancer. Opening the study
represents an important clinical and commercial milestone for Novogen.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Kimberley
Lilischkis, Clinical and Regulatory Affairs Director, commented, &#147;the commencement of this trial represents a further step in Novogen&#146;s transition to a clinical-stage drug development company, and we are excited to be working with leading
clinicians in the US and Australia on this critical project.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Novogen is focused
on developing treatments for patients with the highest unmet medical need and those who are inadequately served by existing therapies. We hope that Cantrixil will have the potential to offer a meaningful new treatment option for patients with
ovarian cancer,&#148; she said.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Cantrixil phase I study is designed primarily to
assess the appropriate dosage, safety and tolerability of Cantrixil when administered to patients with ovarian cancer who have failed at least two prior lines of chemotherapy.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Although the study is not designed to assess efficacy, patients will also be monitored for radiological evidence of disease response, and exploratory
biomarkers will be assessed. In addition, after an initial period of treatment with Cantrixil alone, clinicians will be permitted to add other approved therapies, which will provide useful information regarding the ability of Cantrixil to be used in
combination with standard-of-care chemotherapy.</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g283688txpg3b.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g283688tx_pg04.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The study will begin by administering Cantrixil at a low dose, and this will be systematically increased as
the study progresses until a Maximum Tolerated Dose (MTD) is determined. Cantrixil will be administered via direct infusion into the intraperitoneal cavity, which is a route that has shown evidence of improved outcomes for some patients with ovarian
cancer.<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> Intraperitoneal chemotherapy is recommended for certain patients with ovarian cancer by the National Comprehensive Cancer Network in the United States, based on the results of a phase III
study conducted by the Gynaecological Oncology Group and reported in 2006.<SUP STYLE="font-size:85%; vertical-align:top">2</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Up to 60 patients will
be enrolled across approximately six hospitals and research centres in the United States and Australia. The study is expected to take approximately 18 months to complete, although the actual duration and number of patients may be altered by findings
observed during the course of the study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Gordon Hirsch, Chief Medical Officer, added, &#145;I would like to congratulate the entire Novogen team for
achieving this important milestone in Novogen&#146;s efforts to develop therapeutic advances for patients suffering cancer. The study has commenced on schedule, in line with the company&#146;s prior guidance of a start in the fourth quarter. We look
forward to progressing the study, while also moving forward as swiftly as possible with the other molecules in our pipeline.&#146; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantrixil is a novel,
first-in-class development candidate from a proprietary drug discovery program conducted in-house by Novogen. Preclinical data from researchers at Yale University has shown broad-based evidence of activity in ovarian cancer<SUP
STYLE="font-size:85%; vertical-align:top">3</SUP>, and results from a preclinical toxicology program were presented at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, LA in April 2016.<SUP
STYLE="font-size:85%; vertical-align:top">4</SUP> Novogen successfully opened an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) in September 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Cantrixil study is publically registered via the US National Institutes of Health at <U>https://www.clinicaltrials.gov/ct2/show/NCT02903771</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ovarian cancer is the most common cause of cancer death from gynecologic tumors in the United States. Around the world, more than 200,000 women are estimated
to develop ovarian cancer every year and about 100,000 die from the disease. Despite advances in the treatment of the disease, the prognosis remains poor, with a five-year survival rate of around 25-40% for patients in the more advanced stages.
There remains a critical need for new therapeutic options to improve the outcome for patients suffering with ovarian cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[ENDS] </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Media and Investor Relations</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Investor Relations (US)</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Glen Zurcher</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E:
<U>glen.zurcher@irdepartment.com.au</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">T: +61 420 249 299</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Robert Kennedy</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E:
<U>robert.kennedy@novogen.com</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">T: +1 212 519 9832 / +1 646 662 3574</P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP
STYLE="font-size:85%; vertical-align:top">1</SUP> Jaaback, K, Johnson, N, and Lawrie, TA, Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. <I>Cochrane Database Syst Rev</I>, 2016(1): p.&nbsp;CD005340.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP> Armstrong, DK, Bundy, B, Wenzel, L, et al., Intraperitoneal Cisplatin and Paclitaxel in Ovarian
Cancer. <I>N Engl J Med</I>, <FONT STYLE="white-space:nowrap">2006;354:34-43</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP> Alvero, A.B.,
et al., <I>TRX-E-002-1 induces c-jun-dependent apoptosis in ovarian cancer stem cells and prevents recurrence in vivo.</I> Molecular Cancer Therapeutics, 2016. <B>15</B>(6): <FONT STYLE="white-space:nowrap">p.&nbsp;1-12</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP> Lilischkis, K., et al., <I>Preclinical toxicology of TRXE-002-1 (Abstract LB201)</I>, in <I>Annual
Meeting of the American Association of Cancer Research</I>. 2016 AACR: New Orleans, LA </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g283688tx_pg04.jpg" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g283688tx_pg04.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the Cantrixil (TRX-E-002-1) development candidate </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantrixil is a cyclodextrin-based formulation of the active ingredient, TRX-E-002-1, which has shown in vitro and in vivo anti-cancer activity in a range of
tumour types. The Company anticipates that, if approved, the drug product would be used as an intra-peritoneal chemotherapy, either alone or in combination with other agents, and in one or more cancers of the abdominal or pelvic cavity (e.g.
ovarian, uterine, colorectal or gastric carcinomas). A first-in-human clinical study in patients with ovarian cancer is currently underway. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
Novogen Limited </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Limited (ASX: NRT; NASDAQ: NVGN) is an emerging oncology-focused biotechnology company, based in Sydney, Australia. Novogen
has a portfolio of four development candidates, diversified across three distinct technologies, with the potential to yield first-in-class and best-in-class agents across a range of oncology indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme. Licensed
from Genentech in late 2016, GDC-0084 is anticipated to enter phase II clinical trials in 2017. Three further molecules have been developed in-house from two proprietary drug discovery platforms (superbenzopyrans and anti-tropomyosins) to treat
ovarian cancer and a range of solid tumours. Cantrixil, the most advanced of these, commenced a first-in-human clinical study in patients with ovarian cancer in late 2016, while Anisina and Trilexium are in preclinical development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit: <U>www.novogen.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g283688tx_pg04.jpg" ALT="LOGO">
 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g283688tx_pg04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g283688tx_pg04.jpg
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M+W)D9CI21$8^(#PO>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^T
M2%!H;W1O<VAO<" S+C  .$))300$       /' %:  ,;)4<< @   @ " #A"
M24T$)0      $/SA'XG(M\EX+S1B- =8=^O_[@ .061O8F4 9,     !_]L
MA  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M @(" @(" @(" @(# P,# P,# P,# 0$! 0$! 0(! 0(" @$" @,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P/_P  1
M"  ^ L8# 1$  A$! Q$!_\0 R@ !  $% 0$! 0            4! P0&!P@"
M"0H! 0 " P$! 0             $!0$#!@('"!   0,#  8' 0D+"P('
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M+6X8)(9HS5CV'I'2"#H(.D'0=*@RBXO=EHT=):NV[UM7;34K<EHT9"P>P@"
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M<)(*F*9KM@>TM-.T;PJLC4CY<?=Q:3"]PVL >/FDE8!AD$&A!!'000>XH"B
M( @" ( @" ( @" ( @" (#U-Z:?P;C?IK_\ U<GFJC+_ %$O0=[P'^60ZY?B
MD;VHQ<&3%9W4WZN"0C:1N-_&?NM0$C%A)W?K98X^H5D/@ /% 2,6'M(R"\R3
M$4-'G=;HZ"UNDCW4!*-:UH#6@-:T4  H !T #4@*H @" ( @" ( @" ( @"
MC,EJA[7^\U 12 ( @" P7_'=_./OH#Y0!#*VG)<E_N%]_G+C^T<I<?"NHYF_
M^IG]Y^LP5[/ 0$1G_P#8\M_D)_R5LM?F1^\0\_\ 17O]MGGY6QPP0! $ 0!
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M?AD>7*5T'2#T*Y/FA^I'V!P!R!SZ  !_S.ST 4'^PVW0N0\Q_J+?W/\ ,S]
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M_24F1PWB&+^HLW(KGI5=JJN\URH-=.K7U=NQ;2%4( @" ( @" ( @" ( @"
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M4#W;R3R/ROZ=\O6G*_*&*BQ6(M'/DX;7/FN;JYEIQKV_NY2Z>\O)RT;SWG4
M  T #G<C(O95UWK\JS?9Z%R'U[A7".'\$PH\/X9;5O&CR;6V]LI-ZRD^5OT4
M6AMBTED$ 0! $!4:CV?=" '6>T^^@*( @+4DT<0&^=)U-&EQUZ:= T=* Q'7
MWR(_=<?N#S0&.ZZF=]]NC8T;OCK0%@N+M+B2=I)/OH"B ("H)&HD=B P)L9C
M+F43W&.L)YQ2DTUE;2RZ-7Z1\3G&G:O2G-*B;IUFF6/CSEOSMP<^=Q3?J,Q^
MB*1HT-$4@#0*- #'4 :*  +$?$NLVO2-%LH<14PYA[0L@( @" ( @" ( @"
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M+CX:$PF8@UK.XO%>CX(#6:.Q8<V^@D0Q+$.2KZ238QD3=V-C(VC[UC6L'<T
M+QMVDA)15(I)%Z+XX_ETA#)?9))&:L>]G\UQ'O(#,9DKEOQG-D_GM%>]N[I0
M&8S*L-.)$YII2K"'#MH=T^^@,Z&YAG)$;PYP%2VA#@*TK0@:*H"^@" ("HU'
ML^Z$!4@5.D:SMV]B I0;1X^2 4&T>/D@(>Z'Z=]3TBGQM6Z.I 8]!M'CY(!0
M;1X^2 4&T>/D@%!M'CY(!0;1X^2 4&T>/D@%!M'CY(!0;1[M:>[44H@.<9"U
MY<EED?:906K]YV]%[-=SV^_73PW-A!:TG87-V*3%W$O>544MVWAR=;<]U]3:
M]1KDT,<9I'=07 VQ-N6]XGMXJ>*V5KR$.44GI)->GVI%F@VCQ\ED\B@VCQ\D
M H-H\?) *#:/'R0"@VCQ\D H-H\?) *#:/'R0"@VCQ\D H-H\?) *#:/'R0"
M@VCQ\D H-H\?) 1>:#?JV?><W7#N[U?C<9FJHUTJMMGQKF(?$/TDN?2G77Z*
MFA4'RA\[\U33GQ0?*'SOS4 H/E#YWYJ \^>I(]679B^'+[LHSEMK+<6IPWL_
M'>?9HS<F3V0/RE1<;XT@"FK1166+\GN+XN[\7I_?H<EQC^/?,2^4^)\I14W*
M5V*M:>]MK[#S-?MO_:'?6K[SVJIWOK+VSVFM=-?:V<76K6.[3W*4Z*>PXV[\
M3??Q][XGVJU[R]B8;V2[8W&74UO<EPW9+(9(S@UT4&,MI[GN:L3<4O>55TT]
MIZL*ZYI6&U/[.]7_  JI['](,3S2W.XUW/G-.6?RJ67!O8;G&78N!2VD-JV.
MXOK%N7&_<!H)9&[03JUJCSIVOA2^7A'X_)JOIH?0?+UG.^<A_%KUS^'T>]6+
MKLTU:W]M-BJ?HYA!B?JFQ^HS!]5<!OL7 W^'PJFM=X<3B;]=_>^%O5KI7,W-
M_??Q*[]=3[1B_+_+P^4I\O3W:?M7KKK4E*#:/'R6LD"@VCQ\D H-H\?) *#:
M/'R0"@VCQ\D H-H\?) *#:/'R0"@VCQ\D H-H\?) *#:/'R0"@VCQ\D H-H\
M?) *#:/'R0"@VCQ\D H-H\?) *#:/'R0"@VCQ\D!&Y&]N;*(OM<1?Y>2AI#8
MS8J UV.DRF1L&-KU;R]PC&3]Z2BNFOL3--Z[<M1K;MSN/FBX+\4HG+\QS-ZP
M2\2/E_TUL;1IWA'<Y?F7"WDH%:-?[-:Y*UA:X#30R/"EPM8*UNW6^J+7L.>R
ML_S-*L<+!A'F<[L)/KHII>BK.+<UG[1,L,TF4;FK:S+7&6'EOV(PM9NC>#C@
M'W-SN[ORGE3[/\+36YNN7VJ^W0Y;B#\[RBW?5V-OE5K=I_\ &V^\T?D]O)X-
MT>>'M=G/:Z0-SGUG7V;@L^%)QV"+>XI=7B&O4MF3\Q5?+?ET^K3:0>#+@])/
MC37SN_I\3?V46VNFVNT[YBQB. SZE.-]FW1N_5GL_#W::*^S#9M53/XF]_JU
MKTG?8WRFXOD_A[E/J;NST&TLW3 WB[@9N .XM"PBFL[PW:'K7E=!.=-SWO#T
M[#5,L.63#. ZS;=\.3A&UXE>-NG<#O9VF+2[Y6A;8?$Z:?MSE9E?P_=?@^-3
M2G/Z-#0J#Y0^=^:I!2"@^4/G?FK %!\H?._-0%"&TTN;3KK3\E9&G*3V(',6
M\/J5V3&K_"^T<&E?OJMX%*ZZK5/X7U]VI,QEFU_\;XGHK3Z#HEE<^H=N&^T8
MZTOXZ#1<36,$W:7PW,;@>UI4>2QGL;3])=6[G&X>.$9QZ7%/N:]1M5GD,K+1
MM]@+BT=TO@OL;<Q:MANH91IZBM4HP7ADGZ&6%J]D2TNV91?1*+7K3)QN\14$
M@4^$-- .D.I5M-O0M9*Y.@YMS7_]6?"_Y/\ \9,Y::ENY]8@5%:?5G]^K7J*
MDV?F_P#E;].[OT*'B'_KW_W_ (&]_B_P^\<6RF&]%KO>=BN;\GB'Z:,.,S.0
MMM[HHRYQ<<^Z.J56$)Y\?'",EUI>TYC(Q?*US7'R;EI_=G)=\*]YSC*8C$69
M<[&\UXO+QBNXUN.S]A<N'0#'<XOV<./TM%*A.Y+QP<?2G[2COXV/;=;&1;NQ
M^[<B^QQIWD!0?*'SO);2(*#Y0^=^:@+T$,<T@9)=VUHTZYKEMVZ-O:+2UNIC
M[C"L2=%L;[/:T>H14I4<HQ7.ZT[DWW'HWD''8B# 1L/,%O>Q^UW3C+8V.2CC
M#W%F]$#?V5O,2RFD\, UT*GRY3=YMQ:ETT]C9W? [&+#!2^,IK>EK&,J;=GO
M)/N.BP,Y<:0.*R1VCX5R+@#N?%'%X*+_ *A?VU@+8Z]=?:;%"(-P>SF#A]'!
MW=W_ ,,46MUY2=#<I[E*=!=H-H\?)8/0H-H\?) *#:/'R0"@VCQ\D!<C'PM8
M\=HZD!<H-H\?) *#:/'R0"@VCQ\D!(XT#VD:1^J?M^4.I 3]!M'CY(!0;1X^
32 4&T>/D@*@"ATC5U[1U(#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g283688txpg3a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g283688txpg3a.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ C +& P$1  (1 0,1 ?_$ -,  0 !! ,! 0
M       % 08'" (#! D* 0$  04! 0$!            !0$" P0&!P@)"A
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M,6Y3M79;YWDJU\EDN*M5?0MZV^0LZD]]%3IW*C^$WIYP:V[.;=M>K+UH?/\
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M;YCR*;42G7AJD@@Z>0\: N.@% 5'0?1]L4 /2?2?EH"E * 4 H!0"@% * 4
MH!0"@/!<KI;K/&5+NDQF''3KHIU8"G% 'L,MC5;RSIP"035T(2N.D%5F&_D6
M,:'/D24(]O3W+I,'Y+NO,E=Y$QUI4".>9)N+X29K@\BF&^TW&'43S+]%2-K#
M4?6N.K[#E,[S!<NIV\-<L.#DUKZ.HPO<WGI#,MY]UQ]YU*E.//+4XZXHD:E;
MBR5*/PUNI**I%41SDG*4G.;;D^+;J6,>D^D_+0H4H!0"@% * 4 H!0"@% *
M4 H"H)&GF.HZP>L'I% 9%QK<F\V,-QIA-VMR=$AF0X1)80-!I'DGF5H!T)7S
M#T5JW<6W<UCZLB9P=[R<.D+E;ME=#>J78S/=ARFRY&SSVV4"^E(+T)XI:ELZ
M_A,E1+B=?OD%2?/4=<L7+7MK0Z_$S\;-5;,M>IZ-%P?9\736+CJ;HH!0"@%
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M@Y$K4G2BFDZPN1_<N0<9P_=DC8NWL*C16VU#19YEK'4IS3A\"=!6R<X>R@%
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M&<4!)VD$RM=#H&U:^;70#XR* N6@% 5'0?1]L4 /2?2?EH"E * 4 H!0"@%
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M-N?;"5$\#6E>D&QV#;J93EGB&\3>UUV%K_=C9]>RPQ!46$IBYD;@;?N9-?\
MZWF%]:9Y%R; CZ(;[IKL]KIJE-*@SQ5 * 4 H#Q.?/5Z: X4 H#$US_:,_\
MQDC]8JM^'LKN.:O_ -3/O?TGAJ\QB@(F_P#[#NW^GROU1J^U[:]'TFGG_P!%
M>_E/Z&:]5*G!B@% * 4 H!0"@% * 4 H!0"@% * Q/O-QQ!G7_YR!^HFZ?"*
MW=O_ !W]E_4<QYMI^5QK_P!9?=D6_MKXC,TP/N+;<7%Y7C:.5 MUSD+,^"T.
M&EKNBN=YM*4]#3O>-\-!RUDS-IQ\KU[?J7NM<'Z#1\N^?]YV1+'R6\K;UHHS
MD^:*_<GT=BE5'TPV7SW']V+'<;OC2IC3-NGL0[G'N,4QY$.8]%$D1P0IQF5]
M$K7G0HH^2N1SL.]AW5;NTU553I7U'T!Y8\P[?YBPYY.W^)2$U&:G&CC)QYJ<
M6GWIT9GB-$9C#5M.J_*XKBKSZ=0K2.F/5K0"@% * J.@^C[8H >D^D_+0%*
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M$^V$E*B69M]G:+MK>;'BSMV&U=4YSN4M3]6<X\\I<KMJDFUJX\R+O+?FS/\
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M!MOCF.;=7^UYLWC&-W^ZVXY;N9FLS'I-PA8OAN&XTU(EN2ICC7?/AIID+<6
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MN-R2=.+H^)C3I.IXD\23TDGI.OGK;22X'/\ :*J!0"@% * 4 H!0"@% * 4
MH!0"@% * 4!B?>;^$&?]<@?J)M;NW_CO[+^HYGS;_:X_SE]V1JY4R>:GU%\
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M/_-]N_X&FN1\Q_CV_L?\Q]!?!S^T9O\ N8_<1OA7.GKXH!0"@% 5'0?1]L4
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M6V=-%",SJ6XX/6-5^>M.Y>G<T>B.IP]LQ\1J:7-=7ZSZ.[J+LK$2 H!0"@%
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MEG[G\QY4_N3LUJ> X'+\! T)T3Q/17G?DRO_ )C9;X^+>?\ ^,S[ _R/<?\
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M4XXLZ:Z)0D%1]/15KDH\>!?"$[DE&";D^"6IDRS[;/OH#UZDJAZ@$1(I;6^
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M&U:+DJ2?*OL^S6M<RYS?+#2-?236%Y?L8\?%RWXMVG#]5/LZR$ "0$I 2E(
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MBU>I,UC-PJ.GX#\AH"">_*N_I%_C&@/*_(CQ6^]E/LQF]2.=]U#2#IIT*6H
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MR8X1'O"%3&1HD2VP!*0.MQ)(0^!_W5>FM>YCJ7L:/YB:Q=XN0]3)7-'KZ?\
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M$=!' T!-6^4MQ19<)4>4J0H].@(!23Y>F@):@% * J.@^C[8H >D^D_+0%*
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M)E!ONI#++CP<:[(<+:"K1Q'S5:A/3TU?";3H:.9B6;D)74DKB5:HQG6R<\N
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@7U?A4!/]CVO50#L>UZJ =CVO50%1R:'YW1YNL4!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g283688txpg3b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g283688txpg3b.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ .@+& P$1  (1 0,1 ?_$ ,H  0 !!0$! 0$
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M6R<]W&@&NEZV3GNXT UTO6R<]W&@&NEZV3GNXT UTO6R<]W&@&NEZV3GNXT
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ME0O;9]Z.Z^A,HKCTWQJEIH5O%7-.47L;P[3G]RI]O;/B;D=J*1@)&MDJ;BZ
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M%2"G3:<'DUD7%@]! $ 0&UV8849)W97X<.&KS>! 2J ( @" ( @" ( @" (
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MD2R\&\("4M/TD_%N_*$!LB ("IN9_HCW[4!2@" ( @" ( @" (#Z 2< "3O
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MA98!L9:3++)(=.NQ:T!C3_GJ@9\7.P\"J+OSY?3D.^X%^F0Z9?FD=*CH:2+
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M02 X%E933TSL=X:YC [O8J5&<9K&+3125:%>@]VO"<)?O)KVF&O1J" ( @"
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MFGW,M7QE?_'U*I[OSW].1'?<"_3*?7^:1O:CEN$ 0! $ 0! $ 0! $ 0! $
M0! $ 0! $!3(]D4;I9GLAB;E=+*]L431ONDD+6-'=*+3H69B345O2T17*S0;
MSVJ]GU@<YM=M-033QXXTEL<^Z5)(')#:%LT;7>DYJE4[*YJ]V#PY]'M*:Z]0
M\%M&XU;B#FN2/VW_ *<5M9JE5VG4$S6SVVVU4S:A@GB=7.;2>1,-8S2A9KI
M=%V48A9_XLD\)-=1K?'J,H*="$FI)-;VC/3EI9K%5M]M#.3JI*:C9EP;3T['
M.&._)4:YQP[RV*WI<N+(-3C%Y/NN,%S+WO$Q(]M-I6.TO:1DS>3+3TKFG-D(
M$(SKUX-+## UKBE\OOX]2^HGZ/M(KF8-K[?35(R8R4SWTTF&[Y#M=&3S5K=M
M'[K:)E+C=6*PK0C+G3P^LVNBV\L%5@)I*B@><,14PET8W_A8#(/" M,K>HLL
M&6%+C%G4[SE!\Z]ZQ-D94VN[PEC)J"YP.&6(FGJV$'/I0OT\.^%JPG!\J9.4
M[>YC@G"I!\FA]AI]U[+MA[KIF6QQ4,SSB9K5)+;W@[^JB)IMW=C*WPN[B&4F
M^G25EQZ?X1<Z945">N#W>Q:.PYO=.P.G=I/LFT$L60EM/=:5LS<=P>M4AC<
M.&(E2H<2E_4CL**X]'0>+M*S3U37OCA[#G%T[(MN;9I.9:X[K"T$ZVU5,=2<
M!NFGDU%5FWF%2X7UO/-X/G**X]-<7H94U4CK@\>QX/L.>UE#6V^0PU]'5T,H
M)!CJZ>:F?B,XPF8S%2HRC)8Q::*6I2JT9;M:,H2U237M,5>C6$ 0! $ 0&?0
MVNXW-Y9;Z*HJW-Y6IC+FLQS:<F2-F/"0O$ZD(+&;21OHV]>X>%"$IM:E[\C<
M*+LYOU1HNJGT=O8<XEE,\P'Q=.',Q[KPHT[VE'1'%LM*7 ;VIIJ.$%SO%[%]
M9MM%V:6F+ UU965KMUD>A21'O-ULI'Z04:5]4?=27:6E'T_:Q\Z4IRU+[*][
M[3>;7L=;Z;1=;[%"'##_ #$D&L?W=?5%QR<!4>I7JR[\BYM^%4*?R]%)ZVL>
MV1MT.SU4X#72Q0M'N6XRN PS #18/"H[FBTC8U7WVDMO["4BL%$S RF6<C/I
M.U;.;'@[#OKRYOD),+&C'O8R).*EIH.A@BCPW6L&ESR"[QKRVWF28TJ<.Y%(
MS&$XYSFW^$+![,R.JJ(\-"5X W"=(>!V(0&8RZRCI(V/]'%A_P 0\2 S&7*G
M=RM.,^<W2'A;B?$@,UDL<H)C>UX&?1..'=&<("M $ 0%3<S_ $1[]J I0! $
M!%5G3;N89\V;W/!_>@,1 $ 0! $ 0! 4NY#\W1OY7)Y#L_ LK-&)=U]!Q-W*
M=FSG-FSG-P;RL%DN@YAYOI/BR8" ( @" ( @" ( @" ( @(7:'[/'(Z:+I.7
MN]!P[_FK92[Y XE\OR=Y?1&CJ4400! 6I>CDZ7,>AZ7,.B\[>X5E9F)=UY]6
M9Y)[4?I4W]2>5_OGV+RQT'F?FJXM,EY75F<#QOOOYO\ C[G47>ROZ3#_ %)S
M_P"S?87[;S-]+S+^EUYFS@7F1^;_ (.YUGK*/D,Z3DCI>ES?K//W^%5+RY.H
M[F/7UGK'L[^YMFZ'HY^AS?2I^D_Y_P"?YV*H[GYB69]"X)^FT\N7++-]NOGQ
M-T6@M0@" ( @" ( @" ( @" ( @" ( @" (#&K/HTWTWD'[/^F_]OYZRL^3K
MR-=7RI=_+[O>ZCPCVJ?:4W]2NE_^Z?9V<]!YN]P+I+3+^EE]W,^2>HO-E\_G
M_7RZO<2?9UR&?</..3]L<H9O.WE&O?\ =_Z2Q].Y+Y#J\P[9=OHS?L?HV_:/
M+S'H^%5\.OJ.ON_+7E9?>SZCFLO+=T>?]3T?Z/ I*R.?EWGEGR9=1;63 0!
M7:;IV=/RA]%^D;G1^=O+#R/4.^L^K/J.[;+_ $5OWCY/^\]%^R4"KWON]1UM
MAY?]?^/W&UK26(0$1M%]FR?8/(=]Y_L[-^5;*7>^]_#F1;[R'Y/^[W#Q+M;]
MJ3?=;EN^ZWT//N\*OZ/=^_\ Q'RCB/S#^7S?D]TU9;RO" ( @ SK#R,K,[UV
M=?=MO1_3ZOH^5RF]+YWYOFX*JO?.Y?=U':\!_3E^.7MY?=S&]#..[NYN^H9<
M&U6CDC[+_1^D[GC7B63SS+.TR_I]69LIS[O?SK46!\0! $!6S/WO[P@+J (
<@).V=.[XIV;TV<K^Y 3J ( @*FYG^B/?M0'_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
